<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="41962"><DrugName>besifovir</DrugName><DrugNamesKey><Name id="43104067">Besivo</Name><Name id="42954995">besifovir</Name></DrugNamesKey><DrugSynonyms><Name><Value>LB-80317</Value><Types><Type>Analogue</Type><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>LB-80366</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>LB-80372</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>LB-80373</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>LB-80380</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LB-80397</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>LB-80398</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>LB-80400</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>phosphonate nucleosides (oral/prodrug, HBV), LG Chemical</Value></Name><Name><Value>phosphonate nucleosides (oral/prodrug, HBV), LG Life Sciences</Value></Name><Name><Value>ANA-317</Value><Types><Type>Analogue</Type><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>ANA-380</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PMCDG dipivoxil</Value></Name><Name><Value>PMCDG</Value></Name><Name><Value>LB-80331</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>LB-80920</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>DNA polymerase inhibitor (oral/prodrug, HBV), LG Life Sciences</Value></Name><Name><Value>besifovir</Value><Types><Type>INN</Type></Types></Name><Name><Value>LB-80380 maleate</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>besifovir dipivoxil maleate</Value></Name><Name><Value>Besivo</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>441785-25-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22235">LG Chem Ltd</CompanyOriginator><CompaniesPrimary><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="22235">LG Chem Ltd</Company><Company id="27894">Anadys Pharmaceuticals Inc</Company><Company id="30057">LG Life Sciences Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="41962" type="Drug"><TargetEntity id="325503" type="siDrug">Besifovir dipivoxil maleate</TargetEntity></SourceEntity><SourceEntity id="17101" type="Company"><TargetEntity id="4295881034" type="organizationId">Ildong Holdings Co Ltd</TargetEntity></SourceEntity><SourceEntity id="22235" type="Company"><TargetEntity id="4295882004" type="organizationId">LG Chem Ltd</TargetEntity></SourceEntity><SourceEntity id="27894" type="Company"><TargetEntity id="4295916149" type="organizationId">Anadys Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="30057" type="Company"><TargetEntity id="4295882492" type="organizationId">LG Life Sciences Ltd</TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"></TargetEntity><TargetEntity id="D019694" type="MeSH"></TargetEntity><TargetEntity id="-1284790527" type="omicsDisease"></TargetEntity><TargetEntity id="429" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="138" type="Action"><TargetEntity id="3618" type="Mechanism">Nucleic Acid Polymerase Inhibitors</TargetEntity><TargetEntity id="1065" type="Mechanism">DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="416" type="Mechanism">DNA-Directed DNA Polymerase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Hepatitis B virus infection - South Korea - Nov-2017</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="152">Hepatitis B virus infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="138">DNA polymerase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="1652">Prodrug</Technology><Technology id="102">Nucleotide and derivatives</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2018-02-23T16:10:16.000Z</LastModificationDate><ChangeDateLast>2018-01-05T00:00:00.000Z</ChangeDateLast><AddedDate>2002-10-07T15:07:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17101" linkType="Company"&gt;Il Dong&lt;/ulink&gt;, under license from &lt;ulink linkID="30057" linkType="Company"&gt;LG Life Sciences&lt;/ulink&gt; (formerly &lt;ulink linkID="22235" linkType="Company"&gt;LG Chemical&lt;/ulink&gt;), has developed and launched Besivo (besifovir dipivoxil maleate), a phosphonate nucleoside inhibitor of HBV polymerase, for the  oral treatment of HBV infection [&lt;ulink linkID="1155605" linkType="Reference"&gt;1155605&lt;/ulink&gt;], [&lt;ulink linkID="1939606" linkType="Reference"&gt;1939606&lt;/ulink&gt;]. In November 2017, the drug was made available  [&lt;ulink linkID="1995095" linkType="Reference"&gt;1995095&lt;/ulink&gt;]. In October 2012, Il Dong   was planning on seeking to outlicense the drug outside of Korea [&lt;ulink linkID="1351977" linkType="Reference"&gt;1351977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The program was previously being developed under the research code LB-80317 (ANA-317; PMCDG; besifovir) and its prodrug LB-80380 (ANA-380; PMCDG dipivoxil) [&lt;ulink linkID="464777" linkType="reference"&gt;464777&lt;/ulink&gt;], [&lt;ulink linkID="533708" linkType="reference"&gt;533708&lt;/ulink&gt;], [&lt;ulink linkID="1155605" linkType="Reference"&gt;1155605&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="27894" linkType="Company"&gt;Anadys&lt;/ulink&gt; was developing the drug in collaboration with LG [&lt;ulink linkID="533708" linkType="reference"&gt;533708&lt;/ulink&gt;]. In February 2007, Anadys was preparing a phase IIb trial [&lt;ulink linkID="768077" linkType="Reference"&gt;768077&lt;/ulink&gt;]. In May 2007, discussions between LG and Anadys concerning the global        development plan for the drug were ongoing [&lt;ulink linkID="790623" linkType="Reference"&gt;790623&lt;/ulink&gt;]; in August 2007, Anadys decided to discontinue development of the drug, and all rights returned to LG [&lt;ulink linkID="818218" linkType="Reference"&gt;818218&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By September 2016, Il Dong had filed the drug for approval in Korea [&lt;ulink linkID="1801311" linkType="Reference"&gt;1801311&lt;/ulink&gt;]. In May 2017, the drug was approved  [&lt;ulink linkID="1939606" linkType="Reference"&gt;1939606&lt;/ulink&gt;]. In October 2012, launch was planned for 2017 [&lt;ulink linkID="1351977" linkType="Reference"&gt;1351977&lt;/ulink&gt;]; this was still the case in September 2016 [&lt;ulink linkID="1801311" linkType="Reference"&gt;1801311&lt;/ulink&gt;]. In November 2017, it appeared that the drug had been made available as it was being reimbursed [&lt;ulink linkID="1995095" linkType="Reference"&gt;1995095&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2010, LG was planning to  file for approval in 2013 and to launch the drug in 2014  [&lt;ulink linkID="1116578" linkType="Reference"&gt;1116578&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;By May 2010, LG was planning to file an IND for a phase III trial in Korea in the second half of 2010 [&lt;ulink linkID="1116578" linkType="Reference"&gt;1116578&lt;/ulink&gt;]. In September 2013, the company planned to initiate a multicenter, randomized, double-blinded, parallel, phase III study (&lt;ulink linkID="154154" linkType="Protocol"&gt;NCT01937806&lt;/ulink&gt;; ID_BVCL011) to evaluate the antiviral activity and safety of the drug compared to &lt;ulink linkID="40532" linkType="Drug"&gt;tenofovir&lt;/ulink&gt; in HBV infected patients (expected n = 188) for 48 weeks in October 2013. At that time, the trial was expected to complete in January 2016; the trial in October 2013 [&lt;ulink linkID="1485478" linkType="Reference"&gt;1485478&lt;/ulink&gt;]. By September 2016, the trial had been completed. Besifovir was found to be well tolerated and efficacious, and it did not reduce bone density [&lt;ulink linkID="1801311" linkType="Reference"&gt;1801311&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2009, the Korean FDA approved a multinational, multicenter, open-label, randomized, comparative, parallel-group, phase IIb trial to assess LB-80380 (90 or 150 mg tablet) at 24 weeks compared to &lt;ulink linkID="13486" linkType="Drug"&gt;entecavir&lt;/ulink&gt; (0.5 mg) given over 48 weeks in patients with chronic hepatitis B  [&lt;ulink linkID="995482" linkType="Reference"&gt;995482&lt;/ulink&gt;]. In April 2011, 24 week data were presented at the 46th EASL meeting in Berlin, Germany. In LB-80380 90 mg (n = 34), 150 mg (n = 33) and entecavir  (n = 35) groups, &amp;lt; 300 copies/ml of HBV DNA was observed in 58.8, 63.6 and 62.7% of patients, respectively, and ALT normalized in 73.5, 81.8 and 85.7% of patients, respectively at week 24 [&lt;ulink linkID="1182680" linkType="Reference"&gt;1182680&lt;/ulink&gt;]. In November 2011, 48-week clinical data were presented at the 62nd Annual Meeting of the AASLD in San Francisco, CA. At week 48,  HBV-DNA decrease was -5.30, -5.32 and -5.55 log(10) copies/ml for 90-mg LB-80380, 150-mg LB-80380 and 0.5-mg entecavir, respectively, and 63.6, 62.9 and 58.3% of patients in the respective cohorts had undetectable HBV DNA. Serum L-carnitine occurred in drug-treated patients but supplementation with a commercial L-carnitine tablet stabilized this. Levels continued to be monitored in an ongoing extension study up to week 96 [&lt;ulink linkID="1237386" linkType="Reference"&gt;1237386&lt;/ulink&gt;], [&lt;ulink linkID="1237267" linkType="Reference"&gt;1237267&lt;/ulink&gt;]. In November 2013, week 96  data were presented at The Liver Meeting 2013 in Washington, DC. Comparable anti-viral activity was observed between besifovir and entecavir groups after week 96. The levels of carnitine were normalized in all patients following the administration of carnitine supplements at week 96 [&lt;ulink linkID="1495133" linkType="Reference"&gt;1495133&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2009, the Korean FDA approved a multinational, multicenter, double-blind, randomized, comparative, parallel-group, phase IIb trial to assess LB-80380 (90 or 150 mg tablet) at 24 weeks compared to &lt;ulink linkID="6747" linkType="Drug"&gt;adefovir dipivoxil&lt;/ulink&gt; (10 mg) given over 48 weeks in patients with chronic hepatitis B  [&lt;ulink linkID="995482" linkType="Reference"&gt;995482&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2006, phase II trial data were reported showing that LB-80380 reduced viral load in patients with &lt;ulink linkID="3474" linkType="Drug"&gt;lamivudine&lt;/ulink&gt;-resistant hepatitis B virus infection. The 12-week, open-label, multicenter, dose-escalation study assessed the safety and efficacy of the drug in 59 patients who were given 30, 60, 90, 150 or 240 mg of LB-80380, once daily. Those given the three highest doses of LB-80380 achieved robust viral load reductions in serum HBV DNA of 3.8 to 4.0 log10 units by the end of the study. Furthermore, levels of alanine aminotransferase were also substantially reduced. The drug was safe and well tolerated with no serious adverse events. Further results from this trial were expected be presented in April 2006 [&lt;ulink linkID="650412" linkType="Reference"&gt;650412&lt;/ulink&gt;]. In April 2006, further clinical data were presented at the 41st Annual Meeting of the European Association for the Study of the Liver (EASL), in Vienna, Austria [&lt;ulink linkID="664109" linkType="Reference"&gt;664109&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, clinical data were presented at the 40th Annual Meeting of the European Association for the Study of the Liver in Paris, France. LB-80380 reduced DNA viral load and was safe and well tolerated in 41 patients with &lt;ulink linkID="3474" linkType="Drug"&gt;lamivudine&lt;/ulink&gt;-resistant HBV infection.  Oral administration of LB-80380 (90 mg daily) over 12 weeks reduced viral load by over 99%, an average reduction of 3.9 log10 units. At this time, the company was planning to investigate  higher doses to determine an optimal dose for chronic treatment of patients with &lt;ulink linkID="3474" linkType="Drug"&gt;lamivudine&lt;/ulink&gt;-resistant HBV infection [&lt;ulink linkID="595580" linkType="Reference"&gt;595580&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2004, a multicenter, open-label, dose-escalation phase II trial was underway evaluating LB-80380 for 12 weeks in 36 patients divided into three cohorts. At that time, enrollment for the first two cohorts had been completed [&lt;ulink linkID="558891" linkType="Reference"&gt;558891&lt;/ulink&gt;]. In December 2004, interim results were reported, showing that after 12 weeks of treatment, patients receiving 30 and 60 mg doses had an average DNA viral load reduction of 2.8 and 3.2 log10 units, respectively. Interim data from the 90 mg cohort showed an average viral load reduction of 2.7 log10 units after 4 weeks of treatment. The results also showed that LB-80380 was well tolerated and safe [&lt;ulink linkID="575778" linkType="Reference"&gt;575778&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By April 2004, in a 28-day clinical trial that enrolled 28 patients, once-daily oral administration of LB-80380 had reduced HBV viral load by up to 4 log10 units, or 99.99% [&lt;ulink linkID="533708" linkType="reference"&gt;533708&lt;/ulink&gt;]. In May 2004, further results from the phase I/IIa, double-blind, randomized, dose-escalation trial of LB-80380 were presented at the 39th annual meeting for the European Association for the Study of the Liver, in Berlin, Germany [&lt;ulink linkID="537852" linkType="reference"&gt;537852&lt;/ulink&gt;]. In November 2004, further phase I/II trial results were presented at the American Association for the Study of Liver Diseases Annual Meeting, in Boston, MA [&lt;ulink linkID="567846" linkType="Reference"&gt;567846&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2002, LB-80380 was planned to enter the clinic by the end of that year [&lt;ulink linkID="464777" linkType="reference"&gt;464777&lt;/ulink&gt;], and in April 2003, phase II trials were reported to be underway [&lt;ulink linkID="490551" linkType="reference"&gt;490551&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2007, in vitro data were presented at the 42nd annual meeting of the European Association for the Study of the Liver in Barcelona, Spain. The drug was effective against mutant HBV strains, which were resistant to &lt;ulink linkID="3474" linkType="Drug"&gt;lamivudine&lt;/ulink&gt;, &lt;ulink linkID="6747" linkType="Drug"&gt;adefovir&lt;/ulink&gt;, &lt;ulink linkID="13486" linkType="Drug"&gt;entecavir&lt;/ulink&gt; and &lt;ulink linkID="27471" linkType="Drug"&gt;telbivudine&lt;/ulink&gt;. The  antiviral potency of the drug against 7 of 9 HBV resistant-mutants was not significantly different from its potency against wild type HBV, indicated by a less than or equal to 2-fold difference in EC50. In addition, two strains resistant to entecavir and telbivudine showed a 5 and 7-fold decrease, respectively, in sensitivity to ANA-380 [&lt;ulink linkID="783684" linkType="Reference"&gt;783684&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Preclinical data presented before August 2006 showed that LB-80317 and its derivatives, LB-80366, LB-80372, LB-80373, LB-80397, LB-80398 and LB-80400 produced less  than adefovir [&lt;ulink linkID="464821" linkType="Reference"&gt;464821&lt;/ulink&gt;], [&lt;ulink linkID="464822" linkType="Reference"&gt;464822&lt;/ulink&gt;]. LB-80317 was nearly 100-fold more effective in suppressing HBV DNA levels in serum than &lt;ulink linkID="6747" linkType="Drug"&gt;adefovir dipivoxil&lt;/ulink&gt;. When treatment with LB-80317 was discontinued, rebound of virus replication was delayed over 1 month longer than with any other known anti-HBV agent [&lt;ulink linkID="488843" linkType="Reference"&gt;488843&lt;/ulink&gt;]. LB-80317 exhibited potent and selective anti-HBV activity in Hep G2 2.2.15 hepatoma cells (EC50 value of 0.5microM), but showed low cell permeability and poor oral bioavailability in rats and mice. Research then focused on modification of the purine base moiety to increase cell permeability, and the synthesis of a series of phosphonate prodrugs to improve oral bioavailability [&lt;ulink linkID="464777" linkType="Reference"&gt;464777&lt;/ulink&gt;], [&lt;ulink linkID="464818" linkType="Reference"&gt;464818&lt;/ulink&gt;], [&lt;ulink linkID="464819" linkType="Reference"&gt;464819&lt;/ulink&gt;]. LB-80380 exhibited good oral bioavailability [&lt;ulink linkID="464777" linkType="Reference"&gt;464777&lt;/ulink&gt;], [&lt;ulink linkID="464818" linkType="Reference"&gt;464818&lt;/ulink&gt;], [&lt;ulink linkID="464819" linkType="Reference"&gt;464819&lt;/ulink&gt;] and excellent efficacy in vitro and in the transgenic mouse model (at 0.2 mg/kg) [&lt;ulink linkID="464777" linkType="Reference"&gt;464777&lt;/ulink&gt;], [&lt;ulink linkID="464818" linkType="Reference"&gt;464818&lt;/ulink&gt;], [&lt;ulink linkID="464819" linkType="Reference"&gt;464819&lt;/ulink&gt;], [&lt;ulink linkID="533708" linkType="Reference"&gt;533708&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In June 2005, &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; was granted an option to license Anadys's rights to LB-80380 [&lt;ulink linkID="605219" linkType="Reference"&gt;605219&lt;/ulink&gt;], [&lt;ulink linkID="605263" linkType="Reference"&gt;605263&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2004, LG Life Sciences licensed to Anadys exclusive development and commercialization rights to LB-80380 in North America, Europe, Japan and the rest of the world, excluding China, South Korea, India and countries in Southeast Asia. The parties would share costs for clinical development on a global basis [&lt;ulink linkID="533708" linkType="reference"&gt;533708&lt;/ulink&gt;]. In August 2007, Anadys decided to discontinue development of the drug, and all rights returned to LG [&lt;ulink linkID="818218" linkType="Reference"&gt;818218&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2002, LG Life Sciences was spun-off from &lt;ulink linkID="22235" linkType="Company"&gt;LG Chemical&lt;/ulink&gt; to develop pharmaceuticals, including LB-80380 [&lt;ulink linkID="504415" linkType="Reference"&gt;504415&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;George V Papatheodoridis &amp;amp; Spilios Manolakopoulos, Athens University Medical School, Hippokration General Hospital of Athens, Greece&lt;/para&gt;&lt;para&gt;Submission date: 29 May 2006&lt;br/&gt;Publication date: 02 August 2006&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Chronic infection with hepatitis B virus (HBV) represents a significant public health problem as it is estimated to affect over 350 million people worldwide [&lt;ulink linkType="Reference" linkID="676277"&gt;676277&lt;/ulink&gt;]. A substantial proportion of patients with chronic HBV infection develop chronic hepatitis B, which is associated with increased morbidity and mortality and requires treatment [&lt;ulink linkType="Reference" linkID="673064"&gt;673064&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="676277"&gt;676277&lt;/ulink&gt;]. Ideally, all patients with chronic hepatitis B should be treated; however, the non-satisfactory efficacy of current therapeutic options and the possibility of a very slow progressive course in patients with minimal or mild histological liver disease have influenced the current widely accepted criteria for patient selection. Accordingly, treatment is usually indicated only for patients with HBV e antigen (HBeAg)+ chronic hepatitis B and increased aminotransferase activity, and for patients with HBeAg-negative chronic hepatitis B and at least moderate necroinflammation and/or fibrosis [&lt;ulink linkType="Reference" linkID="673064"&gt;673064&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Agents currently licensed for the treatment of chronic hepatitis B include interferon (IFN)alpha, specifically recombinant free or PEGylated IFNalpha2a, and oral nucleoside/nucleotide analog antiviral agents such as &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="6747"&gt;adefovir dipivoxil&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="13486"&gt;entecavir&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="673064"&gt;673064&lt;/ulink&gt;]. The effectiveness of treatments against HBV has substantially improved over the last decade mainly because of the introduction of nucleoside/nucleotide analog therapies [&lt;ulink linkType="Reference" linkID="673064"&gt;673064&lt;/ulink&gt;]. HBV has significant genetic and biochemical similarity with human immunodeficiency virus (HIV) and thus the field of anti-HBV therapy has benefited enormously from the remarkable research efforts into therapeutic interventions for HIV infection. In particular, several anti-HIV drugs, specifically the nucleoside/nucleotide analogs targeting the HIV reverse transcriptase, are often active against the HBV reverse transcriptase polymerase as well [&lt;ulink linkType="Reference" linkID="349263"&gt;349263&lt;/ulink&gt;]. Moreover, the first two licensed oral anti-HBV agents, lamivudine and adefovir, are agents that emerged from the HIV era [&lt;ulink linkType="Reference" linkID="349263"&gt;349263&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="673064"&gt;673064&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Despite its recent progress, however, anti-HBV treatment still has its limitations. Standard or PEGylated IFNalpha therapy has contraindications, relatively poor tolerability, the propensity for side effects, and limited efficacy, offering sustained off-therapy responses in only a minority of patients. On the other hand, the oral antiviral agents infrequently achieve sustained off-therapy responses and should be given for long-periods, which limits their effectiveness [&lt;ulink linkType="Reference" linkID="673064"&gt;673064&lt;/ulink&gt;]. The most important disadvantage of antiviral agents is the emergence of viral resistance, which is progressively increasing with the prolongation of antiviral therapy [&lt;ulink linkType="Reference" linkID="673064"&gt;673064&lt;/ulink&gt;]. The likelihood of viral resistance arising is greatest with lamivudine, which was chronologically the first available agent and is presently the cheapest oral anti-HBV agent. The wide use of lamivudine during the last six to seven years has resulted in a constant increase of patients with YMDD motif mutant HBV strains, whose therapeutic approach might differ from that of treatment-naive patients [&lt;ulink linkType="Reference" linkID="673064"&gt;673064&lt;/ulink&gt;]. Thus, the demand for new oral antivirals with rapid and potent activity, or that target novel steps of the viral cycle, and which would be active against wild-type and lamivudine-resistant HBV strains, remains an important issue mainly in the effort to reduce the rate of viral resistance and treat resistant strains.&lt;/para&gt;&lt;para&gt;LB-80380 is a phosphonate nucleoside that is currently being evaluated in clinical trials by &lt;ulink linkType="Company" linkID="30057"&gt;LG Life Sciences Ltd&lt;/ulink&gt; (formerly &lt;ulink linkType="Company" linkID="22235"&gt;LG Chem Ltd&lt;/ulink&gt;) in collaboration with &lt;ulink linkType="Company" linkID="27894"&gt;Anadys Pharmaceuticals Inc&lt;/ulink&gt;, for the potential treatment of HBV infection [&lt;ulink linkType="Reference" linkID="558891"&gt;558891&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="567846"&gt;567846&lt;/ulink&gt;]. As LB-80380 is a guanine analog, it is expected to exert antiviral activity by competing with the natural deoxyguanine triphosphate during HBV DNA synthesis by the HBV polymerase. The incorporation of LB-80380 into the HBV DNA chain will result in discontinuation of further elongation of the DNA chain, causing termination of HBV replication [&lt;ulink linkType="Reference" linkID="364729"&gt;364729&lt;/ulink&gt;]. Unlike common nucleosides, LB-80380, being a phosphonate nucleoside, will have the advantage of skipping the requisite first phosphorylation step to reach its active metabolic form [&lt;ulink linkType="Reference" linkID="349263"&gt;349263&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="364729"&gt;364729&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;LB-80380 is a prodrug of a novel guanine phosphonate nucleoside analog, LB-80317, which has a cyclopropyl group in its acyclic backbone [&lt;ulink linkType="Reference" linkID="590505"&gt;590505&lt;/ulink&gt;]. In particular, 9-[1-(phosphonomethoxycyclopropyl)methyl]-guanine (PMCG; LB-80317) and 9-[1-(phosphonomethoxycyclopropyl)methyl]-6-deoxyguanine (PMCDG) were first synthesized in several steps from O-silyl-protected ethyl glycolate. The preparation of the cyclopropanol intermediate, which is considered to be a key intermediate in the development of PMCG, was conducted by titanium-mediated Kylinkovich cyclopropanation. PMCDG was finally converted to an orally available agent, PMCDG dipivoxil (LB-80380) by esterification with chloromethyl pivalate in the presence of triethylamine in 1-methyl-2-pyrrolidinone in 39% yield [&lt;ulink linkType="Reference" linkID="590505"&gt;590505&lt;/ulink&gt;]. The synthesis of LB-80380 was reportedly optimized to produce kilogram quantities, without the need for column purification, with an overall yield of 30% [&lt;ulink linkType="Reference" linkID="464777"&gt;464777&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the SAR study, the elongation of the carbon chain and the substitution of the cyclopropyl group by larger cyclic carbon groups were reported to reduce anti-HBV activity [&lt;ulink linkType="Reference" linkID="464777"&gt;464777&lt;/ulink&gt;]. Elsewhere it was reported that prodrugs based on four types of phosphonate groups – acyloxymethylester, alkylmethylcarbonate, N-alkylmethylcarbonate and fluoroalkyl - had been evaluated [&lt;ulink linkType="Reference" linkID="464818"&gt;464818&lt;/ulink&gt;]. However, no results were provided.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;Similar to all nucleoside reverse transcriptase inhibitors, LB-80380 and LB-80317 act as competitive inhibitors of the HBV RNA/DNA polymerase. LB-80380 and LB-80317 have been shown to have potent and selective anti-HBV activity, being effective against both wild-type and lamivudine-resistant HBV in vitro. In particular, the EC50 value for LB-80317 in HepG2 2.2.15 cells (a hepatoma cell line stably transfected with HBV DNA) was 50 nM [&lt;ulink linkType="Reference" linkID="464819"&gt;464819&lt;/ulink&gt;]. Treatment of cells with LB-80380 was found to significantly reduce the levels of intracellular replicative intermediates of HBV, while the rebound of HBV intermediates was suppressed for several days after treatment was terminated [&lt;ulink linkType="Reference" linkID="464819"&gt;464819&lt;/ulink&gt;]. Moreover, LB-80380 was shown to be 100-fold more potent than adefovir, another phosphonate nucleoside, in the HepG2 2.2.15 cell model (EC50 = 50 nM for LB-80380 versus 5.0 microM for adefovir) [&lt;ulink linkType="Reference" linkID="464819"&gt;464819&lt;/ulink&gt;]. Elsewhere it was reported that the EC50 values for LB-80380 and LB-80317 against wild-type and lamivudine-resistant HBV (in an unspecified cell system) ranged from 50 to 500 nM [&lt;ulink linkType="Reference" linkID="464827"&gt;464827&lt;/ulink&gt;], while the EC50 values for LB-80317 specifically against M204I (or M552I), M204V (or M552V), M204I+L180M (or L528M) and M204V+ L180M lamivudine-resistant HBV mutant strains were 9.5, 1.0, 2.7 and 8.3 nM, respectively [&lt;ulink linkType="Reference" linkID="537354"&gt;537354&lt;/ulink&gt;]. Thus, resistance to lamivudine did not confer cross-resistance to LB-80317 [&lt;ulink linkType="Reference" linkID="464819"&gt;464819&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="537354"&gt;537354&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vivo, LB-80380 was reported to be effective in HBV-expressing transgenic mice, as measured by reductions in serum HBV DNA levels, given as ten daily oral doses ranging from 0.2 to 100 mg/kg. No detailed results were provided [&lt;ulink linkType="Reference" linkID="464819"&gt;464819&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="464827"&gt;464827&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;LB-80317 was reported to be nearly 100-fold more effective than adefovir in suppressing serum viral DNA levels in woodchucks infected with the woodchuck hepatitis virus (WHV) [&lt;ulink linkType="Reference" linkID="488843"&gt;488843&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="537357"&gt;537357&lt;/ulink&gt;]. Treatment for 28 days with doses of 5 and 15 mg/kg/day reduced viral loads by &amp;gt; 6 log10 [&lt;ulink linkType="Reference" linkID="537357"&gt;537357&lt;/ulink&gt;]. The rebound of viral replication after discontinuation of LB-80317 was reported as being delayed by over 1 month longer than with other known (although unspecified) anti-HBV agents [&lt;ulink linkType="Reference" linkID="488843"&gt;488843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;LB-80380 exhibited a favorable pharmacokinetic profile in several animal species, in contrast to LB-80317, which reportedly had low cell permeability and poor oral bioavailability in rats and mice [&lt;ulink linkType="Reference" linkID="464818"&gt;464818&lt;/ulink&gt;]. The oral availability of LB-80380 was reported to range from 20 to 60%, according to the animal species tested, and its maximum plasma concentration (Cmax) and area under the curve (AUC) values were greater than those estimated for an effective concentration of LB-80380, the EC50 being maintained for 24 h [&lt;ulink linkType="Reference" linkID="464827"&gt;464827&lt;/ulink&gt;]. Specifically, intravenous administration of 5 mg/kg in rats, dogs and monkeys was associated with half-lives of 30, 130 and 74 min, respectively, and clearance values of 19, 3.8 and 3.6 ml/min/kg, respectively. Oral administration of 10 mg/kg LB-80380 resulted in bioavailability values in the three respective species of 25, 64 and 15%, Cmax values of 0.9, 5.2 and 1.9 microg/ml and time to Cmax (Tmax) values of 72, 110 and 60 min [&lt;ulink linkType="Reference" linkID="464826"&gt;464826&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The pharmacokinetics of LB-80380 were also evaluated in a phase I/II trial, in which 24 HbeAg+ and HBV DNA+ patients with chronic hepatitis B received LB-80380 orally at daily doses of 30, 60, 120 or 240 mg for 28 days. The systemic exposure to LB-80317 was proportional to the dose of LB-80380 [&lt;ulink linkType="Reference" linkID="657466"&gt;657466&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;As with any polymerase inhibitor, concerns exist over the potential mitochondrial toxicity of LB-80317 and LB-80380. In vitro studies on mitochondrial DNA replication showed no decrease in the amount of mitochondrial DNA or any increase in lactic acid levels in Huh7 cells incubated for 6 or 8 days with 100 microM LB-80317 and its derivatives [&lt;ulink linkType="Reference" linkID="464821"&gt;464821&lt;/ulink&gt;]. Thus, it was suggested by the developers that these phosphonate nucleosides might not have any mitochondrial toxicity. The concentration of LB-80317 causing 50% cytotoxicity (CC50) value in HepG2 2.2.15 hepatoma cell cultures and human cell lines was also reported to be &amp;gt; 2 mM [&lt;ulink linkType="Reference" linkID="464819"&gt;464819&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Because nephrotoxicity represents a potentially severe problem for another anti-HBV nucleotide analog, adefovir, the potential for kidney toxicity of LB-80317 and its derivatives was estimated and compared with that of adefovir. In an in vitro kidney cytotoxicity model, in which human ornithine delta-aminotransferase (OAT) complementary (c)DNA from kidney tissue was cloned by RT-PCR, transient and stable expression of human OAT cDNA showed probenecid-sensitive uptakes of p-aminohippurate and cytotoxicity to adefovir. In CHO cells, the stable expression of human OAT-1 caused approximately 200-fold greater toxicity than in parental non-expressing cells. When these cell lines were used to assess cytotoxicity, LB-80317 and its derivatives caused approximately 50-fold less toxicity than adefovir [&lt;ulink linkType="Reference" linkID="464822"&gt;464822&lt;/ulink&gt;]. Thus, LB-80380 and LB-80317 appear to have a low toxicity profile.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;Two phase I/II trials of LB-80380 have been reported to date, both in abstract form. The first trial was designed to assess the safety, pharmacokinetics and antiviral activity of the drug in HbeAg+ and HBV DNA+ naive patients [&lt;ulink linkType="Reference" linkID="620404"&gt;620404&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="657466"&gt;657466&lt;/ulink&gt;]. This was a double-blind, randomized, placebo-controlled, multiple ascending-dose evaluation of LB-80380 administered at daily oral doses of 30, 60, 120 and 240 mg for 28 days. Cohorts of seven patients were randomized (6:1 active:placebo) at each dose level, while patients were followed for 12 weeks after completing the dosing phase. A median reduction in serum HBV DNA levels of 3- to 4-log10 units was observed on day 28 in all patients receiving LB-80380 at any dose, while serum HBV DNA levels returned to baseline after drug discontinuation [&lt;ulink linkType="Reference" linkID="620404"&gt;620404&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="657466"&gt;657466&lt;/ulink&gt;]. It seemed that HBV DNA reduction was greater with the 60 mg dose and above and that HBV DNA returned to pretreatment levels at a slower rate in patients taking the higher LB-80380 doses [&lt;ulink linkType="Reference" linkID="620404"&gt;620404&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The second study, which was an open-label, multicenter, dose-escalation trial, investigated the safety and antiviral activity of escalating doses of LB-80380 in HbeAg+ patients with lamivudine resistance [&lt;ulink linkType="Reference" linkID="657465"&gt;657465&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="676318"&gt;676318&lt;/ulink&gt;]. In total, 65 patients were enrolled into five cohorts to receive daily oral doses of LB-80380 at 30, 60, 90, 150 or 240 mg (n = 13, 14, 14, 12 and 12) for 12 weeks. LB-80380 was co-administered with 100 mg lamivudine for the first 4 weeks then given alone for another 8 weeks. Patients were switched to adefovir upon discontinuation of LB-80380 and monitored for additional 24 weeks. After 4 weeks of treatment, serum HBV DNA levels decreased by approximately 2.1, 2.5, 2.6, 3.0 and 3.0 log10 in the 30-, 60-, 90-, 150- and 240-mg dose group, respectively. Serum HBV DNA levels continued to decline during the LB-80380 monotherapy period, after discontinuation of lamivudine. At week 12, serum HBV DNA levels had fallen further – to approximately 2.8-, 3.2-, 3.8- and 3.7-log10 reductions in the respective groups. The serum HBV DNA reduction in the dose groups above 90 mg appeared to be higher than the reduction in the 30- and 60-mg groups [&lt;ulink linkType="Reference" linkID="657465"&gt;657465&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="676318"&gt;676318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;In two phase I/II trials, escalating doses of up to 240 mg LB-80380 were well tolerated, alone or in combination with lamivudine, without serious or moderate adverse events attributed to treatment [&lt;ulink linkType="Reference" linkID="620404"&gt;620404&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="657465"&gt;657465&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="657466"&gt;657466&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="676318"&gt;676318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;WO-02057288 (&lt;ulink linkType="Company" linkID="22235"&gt;LG Chemical Ltd&lt;/ulink&gt;) specifically claims LB-80380 (compound 10, claim 4) and its use for treating HBV infection. WO-2004029064 (&lt;ulink linkType="Company" linkID="30057"&gt;LG Life Sciences Ltd&lt;/ulink&gt;) claims novel trans-isomers of alkyl-cyclopropyl analogs of LB-80380. Processes for preparing intermediates for LB-80380 are covered by WO-2005058925 and WO-2005058926, and a process for preparing LB-80380 via novel intermediates is claimed in WO-2006004330 (all published by &lt;ulink linkType="Company" linkID="30057"&gt;LG Life Sciences&lt;/ulink&gt;). The 'new use' of LB-80380 and other phosphonate derivatives (for the treatment of HIV) is claimed by Anadys in WO-2005079812.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;LB-80380, an oral prodrug of LB-80317, is a novel phosphonate nucleoside analog that appears to have selective and potent activity against HBV. Preclinical studies and data from phase I/II clinical trials suggest that the drug has good oral availability and is safe and well tolerated. The agent seems to be effective not only in treatment-naive patients, but in those with &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt;-resistant HBV as well. In particular, initial data from trials in naive or &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt;-resistant patients with HbeAg+ chronic hepatitis B suggested that LB-80380 might achieve a reduction in levels of serum HBV DNA of approximately 3- to 4-log10 units at 4 and 12 weeks, respectively. At the time of publication, no data were available from patients with HBeAg- chronic hepatitis B. The first data from the dose-escalating trial showed that the antiviral efficacy of daily dosing with 90 mg LB-80380 was superior to the efficacy of 30- or 60-mg doses, but not significantly different from the efficacy of the 150- or 240-mg doses. However, the questions of whether different doses of LB-80380 may have different antiviral efficacy when given for periods longer than 12 weeks, and whether HBV DNA levels will continue to decrease with prolongation of therapy are not yet known. In addition, the question of whether different doses of LB-80380 may have different effects on other therapeutic endpoints such as HBeAg seroconversion or alanine aminotransferase (ALT) normalization should also be investigated. Thus, further investigation for the optimal dose of LB-80380 may be necessary. In addition, longer studies are required to evaluate the long-term efficacy and the rate of viral resistance with this agent in both naive and &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt;-resistant HBV patients.&lt;/para&gt;&lt;para&gt;The efficacy of the acyclic nucleotide analog adefovir in the treatment of &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt;-resistant HBV infection has been described [&lt;ulink linkType="Reference" linkID="673066"&gt;673066&lt;/ulink&gt;]. Recently, another acyclic nucleotide analog – &lt;ulink linkType="Drug" linkID="14493"&gt;tenofovir disoproxil fumarate&lt;/ulink&gt; – has been shown to have greater efficacy than adefovir against &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt;-resistant HBV, as well an excellent safety profile. After 48 weeks of treatment with adefovir (10 mg daily), 44% of patients had serum HBV DNA levels below 10(5) copies/ml compared with 100% of the tenofovir-treated patients [&lt;ulink linkType="Reference" linkID="673068"&gt;673068&lt;/ulink&gt;]. This antiviral effect was more pronounced during the first 12 weeks of therapy and exceeded a 4-log10 reduction of serum HBV DNA. Large phase III clinical trials with tenofovir are underway and will provide more insights into the antiviral activity of tenofovir. According to the available 12-week data coming from different studies, LB-80380 seems to be more potent in reducing serum HBV DNA levels compared with adefovir, but not compared with tenofovir.&lt;/para&gt;&lt;para&gt;Long-term viral suppression is currently the realistic therapeutic goal in cases of chronic HBV infection [&lt;ulink linkType="Reference" linkID="673064"&gt;673064&lt;/ulink&gt;]. Although potent anti-HBV agents, like the cyclopentyl nucleoside analog &lt;ulink linkType="Drug" linkID="13486"&gt;entecavir&lt;/ulink&gt;, are coming into the market and their use in the future (or the use of combinations of antiviral agents) is expected to reduce the problems of viral resistance, the use of &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt; monotherapy over the last years has resulted in substantial numbers of patients with &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt;-resistant HBV. The possible future introduction of LB-80380 and/or tenofovir is expected to improve the management of HBV infection in patients who develop &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt; resistance. In light of the expected development of several new anti-HBV agents in the future, however, the place of LB-80380 will depend on its long-term efficacy, resistance profile and its potency against mutant HBV strains with resistance to other agents. Eventually, the role of new anti-HBV agents may depend not only on their characteristics, but also on their cost and the adapted treatment strategy. It is currently a matter of clinical debate as to which strategy to implement: should clinics continue to use monotherapies with agents that have a low resistance barrier, such as &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt;, and switching to new anti-HBV agents on development of &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt; resistance, or should agent(s) with a high resistance barrier be used ab initio?&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-01T00:00:00.000Z</StatusDate><Source id="1995095" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27894">Anadys Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="818218" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-01T00:00:00.000Z</StatusDate><Source id="1351977" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-04-13T00:00:00.000Z</StatusDate><Source id="490551" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-01T00:00:00.000Z</StatusDate><Source id="1351977" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-31T00:00:00.000Z</StatusDate><Source id="1485478" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-26T00:00:00.000Z</StatusDate><Source id="1801311" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-05-15T00:00:00.000Z</StatusDate><Source id="1939606" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-10-31T00:00:00.000Z</StatusDate><Source id="504415" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22235">LG Chem Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-10-07T00:00:00.000Z</StatusDate><Source id="464777" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27894">Anadys Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-04-19T00:00:00.000Z</StatusDate><Source id="533708" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00626"><Name>DNA polymerase</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="22235">LG Chem Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1c2c(nc(n1)N)n(cn2)CC3(CC3)OCP(=O)(O)O</Smiles><Smiles>CC(C)(C)C(=O)OCOP(=O)(COC1(CC1)Cn2cnc3c2nc(nc3)N)OCOC(=O)C(C)(C)C</Smiles><Smiles>CC(C)(C)C(=O)OCOP(=O)(COC1(CC1)Cn2cnc3c2nc(nc3)N)OCOC(=O)C(C)(C)C.C(=C\C(=O)O)\C(=O)O</Smiles></StructureSmiles><Deals><Deal id="107020" title="Anadys to develop LG's LB-80380 for chronic hepatitis B virus infection worldwide, excluding certain Asian territories"></Deal><Deal id="107900" title="Novartis to develop Anadys' ANA-975 for HCV, HBV and other infectious diseases    "></Deal><Deal id="143111" title="Il Dong Pharmaceutical to develop and market LG Life Sciences' besifovir"></Deal></Deals><PatentFamilies><PatentFamily id="1808193" number="WO-2006004330" title="Process for preparing di-isopropyl ((1-(hydroxymethyl)-cyclopropyl)oxy)methylphosphonate"></PatentFamily><PatentFamily id="1811890" number="WO-2008088147" title="Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same"></PatentFamily><PatentFamily id="1837056" number="WO-2005058926" title="New process for preparing diisopropyl ((1-((2-amino-6-chloro-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonate"></PatentFamily><PatentFamily id="2175704" number="WO-02057288" title="Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same"></PatentFamily><PatentFamily id="283180" number="WO-2005058925" title="New process for preparing diisopropyl ((1-((2-amino-6-halo-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonate"></PatentFamily><PatentFamily id="286825" number="WO-2005079812" title="Nucleoside phosphonate derivatives useful in the treatment of HIV infections"></PatentFamily><PatentFamily id="3746414" number="CN-106977548" title="Besifovir compound, preparation method and application"></PatentFamily><PatentFamily id="3926925" number="WO-2018016795" title="Orotate of antiviral drug, preparation method therefor, and pharmaceutical composition containing orotate"></PatentFamily><PatentFamily id="4190951" number="WO-2018164458" title="Granules containing besifovir dipivoxil or pharmaceutically acceptable salt thereof, pharmaceutical composition comprising granules, and preparation method therefor"></PatentFamily><PatentFamily id="4323726" number="CN-108997429" title="Method for preparing besifovir"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Haisco Pharmaceutical Group Co Ltd" id="1063506"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Il Dong Pharmaceutical Co Ltd" id="17101"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LG Chem Ltd" id="22235"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>